Alsidawi et al., 2014 - Google Patents
MicroRNAs in brain metastases: potential role as diagnostics and therapeuticsAlsidawi et al., 2014
View HTML- Document ID
- 17229963446633502199
- Author
- Alsidawi S
- Malek E
- Driscoll J
- Publication year
- Publication venue
- International Journal of Molecular Sciences
External Links
Snippet
Brain metastases remain a daunting adversary that negatively impact patient survival. Metastatic brain tumors affect up to 45% of all cancer patients with systemic cancer and account for~ 20% of all cancer-related deaths. A complex network of non-coding RNA …
- 229920001239 microRNA 0 title abstract description 163
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Forterre et al. | A comprehensive review of cancer MicroRNA therapeutic delivery strategies | |
| Alsidawi et al. | MicroRNAs in brain metastases: potential role as diagnostics and therapeutics | |
| Reda El Sayed et al. | MicroRNA therapeutics in cancer: current advances and challenges | |
| Ji et al. | Targeting microRNAs in cancer gene therapy | |
| Yu et al. | Exosomes as miRNA carriers: formation–function–future | |
| Schwarzenbach et al. | MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer | |
| Dang et al. | The role of hypoxia-induced miR-210 in cancer progression | |
| Bullock et al. | Exosomal non-coding RNAs: diagnostic, prognostic and therapeutic applications in cancer | |
| O’Neill et al. | Nanoparticle-based delivery of tumor suppressor microRNA for cancer therapy | |
| Pozniak et al. | Circulating microRNAs in medicine | |
| Sasaki et al. | MicroRNA-based diagnosis and treatment of metastatic human osteosarcoma | |
| Fujita et al. | Development of small RNA delivery systems for lung cancer therapy | |
| Romano et al. | microRNAs as novel therapeutics in cancer | |
| Desantis et al. | MicroRNAs-based nano-strategies as new therapeutic approach in multiple myeloma to overcome disease progression and drug resistance | |
| Garbo et al. | Next RNA therapeutics: the mine of non-coding | |
| Costa et al. | MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression | |
| Wong et al. | Exosomal MicroRNAs and organotropism in breast cancer metastasis | |
| Liu et al. | The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer | |
| Makowska et al. | microRNAs (miRNAs) in glioblastoma multiforme (GBM)—recent literature review | |
| Pollutri et al. | TP53/MicroRNA interplay in hepatocellular carcinoma | |
| Kirstein et al. | The role of miRNA for the treatment of MGMT unmethylated glioblastoma multiforme | |
| Titze de Almeida et al. | Delivery of miRNA-targeted oligonucleotides in the rat striatum by magnetofection with Neuromag® | |
| Nuzzo et al. | Potential and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision medicine in cancer | |
| Arrighetti et al. | miRNAs as therapeutic tools and biomarkers for prostate cancer | |
| Linder et al. | Therapeutic targeting of Stat3 using lipopolyplex nanoparticle-formulated siRNA in a syngeneic orthotopic mouse glioma model |